Skip to content
Open access

Outcomes following percutaneous coronary revascularisation in acute coronary syndromes: a comparison of drug coated balloon versus drug eluting stent strategies in de novo large epicardial vessels

Oct 2026 · European Heart Journal · 0 citations

TL;DR

The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy, which was comparable to a DES only strategy.

Abstract

Drug coated balloons (DCB) in de novo large vessel disease and in acute coronary syndromes (ACS) remain under scrutiny with a paucity of data. This study reports on outcomes of a DCB only strategy compared to a drug eluting stent (DES) only strategy in large epicardial coronary arteries in an ACS population. Retrospective analysis of prospectively collected data on all ACS patients undergoing percutaneous coronary intervention (PCI) from January 2021 to June 2025. The primary outcome was medium to long term major adverse cardiovascular events (MACE). There were 247 patients in the DCB arm with treated large epicardial vessels >3mm) and they were matched with 247 patients treated with DES. The median age was 64 (58-74) in the DCB group and 64 (57-73) in the DES group. No significant difference in MACE at median 21-month follow-up between the DCB and DES groups (10.1% vs 11.7%, p=0.94, all-cause mortality (5.3% vs 8.1%, p=0.44) or repeat revascularisation (4.9% vs 4.5%, p=0.49) in the DCB group compared to the DES group. The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy.KM Graph of MACE after DCB and DES strategiesFor image description, please refer to the figure legend and surrounding text.

Read PDF

Similar papers

Open access Oct 2026

Long term clinical outcomes of drug-coated balloon angioplasty in comparison to drug eluting stents following rotational atherectomy for calcified coronary lesions: a single center retrospective study

Drug-coated balloon (DCB) has emerged as potential alternative to drug-eluting stents (DES) in specific lesion subsets for de novo coronary lesions. However, evidence supporting DCB in severely calcified lesions remains limited. Quantitative flow ratio (QFR) is a noninvasive quantitative tool for evaluating post-...

Q. Qin, L. Chen, Ren-De Xu et al. · 0 citations
Open access Oct 2026

Less metal, same outcomes: drug-coated balloon PCI in acute coronary syndrome - real-world registry data

Drug-coated balloon (DCB)-based strategies are increasingly explored as an alternative or adjunct to drug-eluting stent (DES) implantation to reduce permanent metal burden. However, real-world data on the utilization and safety of DCB-based strategies in acute coronary syndrome (ACS) remain limited. To eva...

F. Rode, A. Jordan, M. Radić et al. · 0 citations
Oct 2026

Drug coated balloon vs. drug eluting stent in calcified de novo coronary lesions: Long term outcomes from the SPARTAN registry.

AIM Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...

Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al. · 0 citations
Open access Oct 2026

One-Year Clinical Outcomes of Paclitaxel-Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry.

BACKGROUND Real-world data after percutaneous coronary intervention (PCI) using drug-coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. AIMS We compared 1-year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non-ACS patients. METHODS The ALLIANCE is a prospective, multicenter...

Takashi Muramatsu, K. Tanabe, K. Kadota et al. · 0 citations
Open access Oct 2026

Drug-coated balloon–only strategy versus drug-eluting stents in large-vessel complex PCI: a propensity-matched 3-year outcome analysis

In patients with large coronary vessels and ACC/AHA type B2/C complex lesions, a DCB-only strategy demonstrated comparable but not superior 3-year outcomes compared with newer-generation DES, suggesting no procedural simplification advantage with DCB-only treatment.

R. Bando, K. Yamaguchi, Y. Kawabata et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.